Interestingly, a preclinical study revealed that acquired resistance against selumetinib (MEK inhibitor) was attributed by FGFR3-mediated MAPK reactivation in HNSCC, suggesting combined FGFR3/MAPK to resist the development of selumetinib resistance in HNSCC38. The gene discussed is FGFR3; the disease is head and neck squamous cell carcinoma.